Fulvestrant
Fulvestrant is a pharmaceutical drug with 363 clinical trials. Currently 121 active trials ongoing. Historical success rate of 73.1%.
Success Metrics
Based on 136 completed trials
Phase Distribution
Phase Distribution
117
Early Stage
166
Mid Stage
63
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
67.7%
136 of 201 finished
32.3%
65 ended early
121
trials recruiting
363
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Roll-over Study to Allow Continued Access to Ribociclib
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Clinical Trials (363)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Roll-over Study to Allow Continued Access to Ribociclib
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Study of AVZO-021 in Patients With Advanced Solid Tumors
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 363